Quality Control Analyst II
Immatics
Summary
We are seeking a Quality Control Analyst II to support our Global Quality Operations team. The QC Analyst II will be responsible for executing bioanalytical, cell-based, and/or molecular methods for product release in the Quality Control laboratory.
Job description
Role Overview
We are seeking a Quality Control Analyst II to support our Global Quality Operations team. The QC Analyst II will be responsible for executing bioanalytical, cell-based, and/or molecular methods for product release in the Quality Control laboratory.
Schedule: 12:30 PM – 11:00 PM; Monday to Thursday; On-site. Reports to: Associate Quality Control Manager.
In this role you will:
- Perform release assays for cell product identity and safety, which includes the use of different laboratory methods such as visual inspection, cell count & viability, flow cytometry, cell culture, immunoassays, DNA isolation, PCR, sterility, endotoxin, and mycoplasma
- Safely handle human biological specimens
- Extract, compile, and analyze data
- Generate, report, and track results
- Conduct and document all activities consistent with cGMP/GxP, regulatory filings, and written procedures
- Transport controlled documents between OQS office and QC laboratory
- Transport QA-released QC materials between QC laboratories
- Manage, in collaborations with other team members, supply inventory
Travel requirements: Less than 10%, minimal.
Requirements
- BA or BS in any science-related field
- Minimum two (2) years' experience in a regulated laboratory environment
- Laboratory skills including any of the following: visual inspection, cell count & viability, flow cytometry, cell culture, immunoassays, DNA isolation, PCR, sterility, endotoxin, and mycoplasma
- Cell Based Potency Assays
- Experience with LIMS
- Authorized to work in the United States without the need for current or future sponsorship
Benefits
- Health, Dental & Vision Insurance
- 4 weeks vacation
- 12 company paid holidays
- 7 days sick time
- Employer-paid life insurance
- Employer-paid short/long-term disability
- 401(k) with company match
- Partially paid parental leave
- Accident, hospital indemnity, critical illness insurance
- Identity theft protection
- Pet insurance
Company overview
Immatics is a clinical-stage biotechnology company and the global leader in precision targeting of PRAME (Preferentially Expressed Antigen in Melanoma), a cancer target expressed in more than 50 different cancer types. Founded in 2000 as a spin-off from the University of Tübingen's Department of Immunology, the company has grown into a publicly traded entity (NASDAQ: IMTX) with operations in Germany and the United States. Immatics specializes in developing T-cell redirecting immunotherapies, including TCR T-cell therapies and TCR bispecifics, for the treatment of solid tumors. The company's proprietary XPRESIDENT™ technology platform enables the identification of tumor-associated peptides (TUMAPs) with unprecedented sensitivity, allowing for the development of highly specific cancer immunotherapies. With a robust clinical pipeline focused on PRAME-targeting therapies, Immatics is advancing multiple programs including IMA203 (anzutresgene autoleucel) for PRAME-positive solid tumors, IMA402 PRAME bispecific, and IMA401 MAGEA4/8 bispecific. The company's innovative approach combines mass spectrometry, genomics, biochemistry, and immunology to create novel cancer treatments that address significant unmet medical needs in oncology.